iBio Inc. is a preclinical-stage biotechnology company developing next-generation biopharmaceuticals by leveraging artificial intelligence and advanced computational biology. The company focuses on creating novel antibody-based therapies for cardiometabolic diseases, obesity, cancer, and other difficult-to-treat conditions. iBio's proprietary technology platforms include EngageTx for enhanced T-cell engager antibodies, ShieldTx for conditionally activated antibodies, and StableHu for AI-assisted antibody optimization. The company integrates AI with experimental biology to design antibodies targeting previously undruggable proteins, emphasizing precision, speed, and real-world patient impact. iBio's pipeline includes IBIO-101 for solid tumors, CCR8 for cancer immunotherapy, and EGFRvIII for specific cancer types. Through a collaboration with AstralBio, iBio is also advancing novel antibody therapies for obesity and cardiometabolic disease. Headquartered in San Diego, California, and incorporated in 2008, iBio aims to transform drug discovery and accelerate development timelines in precision medicine.